All In Biotech

Drug Trial Radar · NCT04704921

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 671 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

671

Actual

Start

Dec 29, 2020

Primary completion

Dec 2026

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
REGENXBIO Inc.
First posted
Jan 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. Due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.

Conditions

  • AMD
  • nAMD
  • Wet Age-related Macular Degeneration
  • wAMD
  • Wet AMD
  • CNV
  • Neovascular AMD
  • Neovascular Age-related Macular Degeneration
  • Choroidal Neovascularization

Interventions

  • ABBV-RGX-314Genetic

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)

  • ABBV-RGX-314Genetic

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)

  • Ranibizumab (LUCENTIS®)Biological

    0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: At Week 54
  2. Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEsTime frame: Week 50

Locations

89 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Research Institute /ID# 256019

    Phoenix, Arizona

  • Barnet Dulaney Perkins Eye Center - Sun City /ID# 256055

    Sun City, Arizona

  • University of Arkansas for Medical Sciences /ID# 271290

    Little Rock, Arkansas

  • Retina Vitreous Assoc Med Grp /ID# 256299

    Beverly Hills, California

  • Retinal Diagnostic Center /ID# 256137

    Campbell, California

  • The Retina Partners - Encino /ID# 256054

    Encino, California

  • Retina Consultants of Orange County /ID# 256152

    Fullerton, California

  • Salehi Retina Institute /ID# 263485

    Huntington Beach, California

  • UC Irvine/Gavin Herbert Eye Institute /ID# 256145

    Irvine, California

  • Northern California Retina Vitreous Associates Medical Group, Inc /ID# 256298

    Mountain View, California

  • UCLA Doheny Eye Center /ID# 256120

    Pasadena, California

  • California Eye Specialists Medical Group Inc. /ID# 256079

    Pasadena, California

  • Retina Consultants of San Diego /ID# 256021

    Poway, California

  • Retinal Consultants Medical Group /ID# 256047

    Sacramento, California

  • West Coast Retina /ID# 256448

    San Francisco, California

  • University of California, San Francisco /ID# 256130

    San Francisco, California

  • Orange County Retina Medical Group /ID# 256073

    Santa Ana, California

  • California Retina Consultants - Santa Barbara /ID# 256017

    Santa Barbara, California

  • Retina Consultants of Southern Colorado /ID# 256069

    Colorado Springs, Colorado

  • Southwest Retina Research Center /ID# 256136

    Durango, Colorado

  • Colorado Retina Associates /ID# 256121

    Lakewood, Colorado

  • Retina Group of New England - Waterford /ID# 256071

    Waterford, Connecticut

  • Advanced Research, LLC /ID# 275451

    Deerfield Beach, Florida

  • Vitreoretinal Associates, P.A. /ID# 256150

    Gainesville, Florida

  • Florida Retina Consultants /ID# 265661

    Lakeland, Florida

  • Bascom Palmer Eye Institute - University of Miami /ID# 256072

    Miami, Florida

  • Retina Specialty Institute /ID# 256153

    Pensacola, Florida

  • Retina Vitreous Associates of Florida - St. Petersburg /ID# 256050

    St. Petersburg, Florida

  • Southern Vitreoretinal Associates /ID# 256158

    Tallahassee, Florida

  • Southeast Retina Center /ID# 256022

    Augusta, Georgia

  • Georgia Retina - Marietta /ID# 256142

    Marietta, Georgia

  • Marietta Eye Clinic /ID# 268163

    Marietta, Georgia

  • Thomas Eye Group PC /ID# 268159

    Sandy Springs, Georgia

  • Retina Consultants of Hawaii /ID# 256049

    ‘Aiea, Hawaii

  • University of Illinois at Chicago /ID# 256300

    Chicago, Illinois

  • University Retina and Macula Associates /ID# 256078

    Lemont, Illinois

  • University Retina and Macula Associates /ID# 256077

    Oak Forest, Illinois

  • Springfield Clinic /ID# 266225

    Springfield, Illinois

  • Retina Partners Midwest, PC /ID# 256045

    Indianapolis, Indiana

  • John-Kenyon American Eye Institute -New Albany /ID# 256065

    New Albany, Indiana

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.